Pharmaceutical companies remain on an upward R&D trend through 2010. More than 9,000 new drugs have been added to the pipeline this year, showing growth in all clinical stages of development. The pharmaceutical and biotech industries’ top 20 pipeline leaders spent a combined $86.57 billion during 2009. Several leading pharmaceutical companies have implemented large-scale and aggressive M&A strategies.Editors of PharmaLive.com, a leading source for pharmaceutical business, marketing, and clinical research information, have released the second annual Top 20 Pipelines Special Report.
READ MORE OF THIS ARTICLE AT: http://www.drugs.com/news/top-20-pharma-s-r-amp-d-spending-topped-86-billion-2009-28542.html